MeDiGes Study: Metformine Use in Gestational Diabetes
Status:
Active, not recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Women with gestational diabete (GD) who do not meet glycemic control objectives with diet
will be assigned to two treatment groups randomly. One: metformin at a dose of 850-2550mg
every 24h; two: insulin detemir associated or not with rapid insulin analogue (aspart)
according to your glycemic controls. The Metformin group may additionally receive insulin in
a second time in case the glycemic control is not appropriate with monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud